12.07.2023
WA42985 POSTERITY
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Obinutuzumab in Adolescent Patients With Active Class III Or IV Lupus Nephritis
Show more12.07.2023
200075 ZOSTER-047
A Phase II, randomised, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK’s paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) when administered intramuscularly on a two-dose schedule to immunocompromised paediatric renal transplant recipients from 1 to 17 years of age
Show more12.07.2023
ALN-GO1-005 ILLUMINATE-C
ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1)
Show more12.07.2023
DCR-PHXC-204 PHYOX 7
A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 or 2 and Severe Renal Impairment, With or Without Dialysis
Show more12.07.2023
DCR-PHXC-301 PHYOX 3
An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria
Show more12.07.2023
BUR-CL207
A Phase 1/2, Open-label, Multicenter, Non-Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Burosumab In Pediatric Patients From Birth To <1 Year Of Age With Chromosome-Linked Hypophosphatemia X (XLH)
Show more12.07.2023
DCR-PHXC-203 PHYOX_8
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients from Birth to 5 Years of Age with Primary Hyperoxaluria and Relatively Intact Renal Function
Show more12.07.2023
19920 FIONA
A 6-month multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and PK/PD of an age and body-weight-adjusted oral Finerone regimen, in addition to an ACEI or ARB, for the treatment of children, 6 months to to <18 years of age, with chronic kidney disease and proteinuria < .
Show more